Paulson & CO. Inc. grew its holdings in shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) by 20.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 662,056 shares of the biotechnology company’s stock after purchasing an additional 112,056 shares during the period. Paulson & CO. Inc. owned approximately 0.53% of Rigel Pharmaceuticals worth $1,807,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the company. Parametric Portfolio Associates LLC lifted its holdings in shares of Rigel Pharmaceuticals by 11.3% during the 1st quarter. Parametric Portfolio Associates LLC now owns 30,815 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 3,118 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Rigel Pharmaceuticals by 6.0% during the 2nd quarter. Rhumbline Advisers now owns 139,814 shares of the biotechnology company’s stock valued at $382,000 after purchasing an additional 7,910 shares during the last quarter. Marshall Wace North America L.P. lifted its holdings in shares of Rigel Pharmaceuticals by 0.5% during the 2nd quarter. Marshall Wace North America L.P. now owns 1,988,193 shares of the biotechnology company’s stock valued at $5,965,000 after purchasing an additional 9,867 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Rigel Pharmaceuticals by 0.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,461,550 shares of the biotechnology company’s stock valued at $3,990,000 after purchasing an additional 11,836 shares during the last quarter. Finally, Voya Investment Management LLC lifted its holdings in shares of Rigel Pharmaceuticals by 30.4% during the 2nd quarter. Voya Investment Management LLC now owns 53,661 shares of the biotechnology company’s stock valued at $146,000 after purchasing an additional 12,500 shares during the last quarter. Hedge funds and other institutional investors own 77.28% of the company’s stock.

Several analysts have recently commented on RIGL shares. BMO Capital Markets reiterated a “buy” rating and set a $5.00 price objective on shares of Rigel Pharmaceuticals in a report on Monday, October 2nd. BidaskClub lowered Rigel Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, July 28th. ValuEngine lowered Rigel Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Wednesday, September 6th. Zacks Investment Research upgraded Rigel Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, September 20th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $5.00 price objective on shares of Rigel Pharmaceuticals in a report on Wednesday, October 4th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. Rigel Pharmaceuticals has an average rating of “Hold” and an average target price of $6.75.

WARNING: “Paulson & CO. Inc. Has $1.81 Million Stake in Rigel Pharmaceuticals, Inc. (RIGL)” was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at https://www.dailypolitical.com/2017/10/18/paulson-co-inc-has-1-81-million-stake-in-rigel-pharmaceuticals-inc-rigl.html.

Rigel Pharmaceuticals (NASDAQ:RIGL) last released its quarterly earnings data on Tuesday, August 1st. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.01). Rigel Pharmaceuticals had a negative return on equity of 105.86% and a negative net margin of 354.14%. During the same quarter in the previous year, the firm earned ($0.15) EPS.

Rigel Pharmaceuticals Profile

Rigel Pharmaceuticals, Inc is a clinical-stage biotechnology company. The Company is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s pioneering research focuses on signaling pathways that are critical to disease mechanisms.

Want to see what other hedge funds are holding RIGL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL).

Institutional Ownership by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)

Receive News & Ratings for Rigel Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.